_plus-therapeutics-q2-2020-financial-and-business-results.jpg "Plus Therapeutics Q2 2020 Financial and Business Results from encapsulated meaning Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 64 sec
✓ Published: 21-Nov-2020
✓ Published: 21-Nov-2020
Description:
Austin, Texas, Aug. 10, 2020 -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced financial and business results for its Second Quarter Fiscal Year 2020 ended June 30, 2020.nnQ2 2020 net loss was $1.8 million, or $0.45 per share, including payments to NanoTx LLC of $0.78 million. Net cash used in operating activities for the six months ended June 30, 2020 was approximately $2.9 million. Plus Therapeutics ended Q2 2020 with approximately $9.3 million of cash and cash equ
Austin, Texas, Aug. 10, 2020 -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced financial and business results for its Second Quarter Fiscal Year 2020 ended June 30, 2020.nnQ2 2020 net loss was $1.8 million, or $0.45 per share, including payments to NanoTx LLC of $0.78 million. Net cash used in operating activities for the six months ended June 30, 2020 was approximately $2.9 million. Plus Therapeutics ended Q2 2020 with approximately $9.3 million of cash and cash equ
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_plus-therapeutics-reports-q3-2020-financial-results-and-business-highlights.webp "AUSTIN, Texas, October 22, 2020 – Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced financial results for the third quarter ended September 30, 2020, and provided an overview of recent business highlights.nn“Our lead investigational drug, RNL™ for recurrent glioblastoma, continues to progress toward its first major data readout,” said Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics. “In the third quarter, we advanced RNL successful")
⏲ 1 min 13 sec ✓ 21-Nov-2020
_plus-therapeutics-announces-webinar-to-present-respect-glioblastoma-clinical-trial-update.webp "AUSTIN, Texas, Nov. 13, 2020 -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, personalized and targeted therapies for rare and difficult to treat cancers, today announced it will host a webinar on Thursday, November 19, 2020, 4:30 to 5:30 p.m. ET. The call will follow a poster presentation of new interim data from the ongoing National Institutes of Health-sponsored ReSPECT™ Phase 1 clinical trial evaluating the Company’s")
⏲ 38 sec ✓ 21-Nov-2020
_plus-therapeutics-reports-first-quarter-2021-financial-results-and-business-highlights.webp "AUSTIN, Texas, April 22, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced financial results for the first quarter ended March 31, 2021, and provided an overview of recent business highlights.nnThe Company’s lead investigational drug is Rhenium NanoLiposome (RNL™), a radiotherapy in development for several rare cancer targets")
⏲ 93 sec ✓ 28-Apr-2021
_saucer-x-travis-walton-trading-cards.webp "We’ve collaborated with Travis Walton once again to bring you the first official autographed trading cards in Ufology.nnEach signature is on-card, meaning Travis handled each card himself, making them more desirable among collectors. Travis autographed each card beautifully in blue ink on Alien Abduction Day (March 20, 2021) in Heber, Arizona.nnNever has Travis' iconic story been officially told with his collaboration through the art of trading cards until now.nnEach card is encapsulated in a")
_plus-therapeutics-announces-initiation-of-final-cohort-of-respect-glioblastoma-trial.webp "Austin, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that it has treated the first patient in the sixth and final cohort of its National Cancer Institute (NCI)-supported, multi-center ReSPECT™ Phase 1 dose-finding clinical trial evaluating Rhenium NanoLiposomes (RNL™) for the treatment of recurrent glioblastoma (GBM). Initiation of the sixth dose cohort follows successful completion of the fifth cohort and clearance from")
⏲ 45 sec ✓ 21-Nov-2020
_plus-therapeutics-enters-into-master-services-agreement-with-piramal-pharma-solutions-a-leading-cdmo.webp "AUSTIN, Texas, March 23, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that it has entered into a master services agreement (MSA) with Piramal Pharma Solutions (PPS) for the development, manufacture, and supply of Plus’ Rhenium NanoLiposome (RNL™) intermediate drug product.nnThe MSA includes the transfer of analytical met")
⏲ 30 sec ✓ 28-Apr-2021
_plus-therapeutics-respect-clinical-trial-data-to-be-presented-at-2020-sno-annual-meeting.webp "AUSTIN, Texas, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that its abstract regarding lead investigational drug, Rhenium NanoLiposomes (RNL™), was accepted to the 2020 Society for Neuro-Oncology (SNO) Annual Meeting being held virtually on November 19-21, 2020.nn“We are looking forward to updating the medical community on the latest data from our ReSPECT™ Phase 1 trial,” said Marc Hedrick, M.D., President and Chief Execut")
⏲ 27 sec ✓ 08-Dec-2020
_from-blueprint-to-framework-learning-with-matthew-2239-2023-06-21-232351.webp "This session with Elder Michael Johnson as he delves deep into the profound commandment -")
⏲ 42 min 90 sec ✓ 22-Jun-2023
_plus-therapeutics-reports-q3-2020-financial-results-and-business-highlights.jpg)
_plus-therapeutics-announces-webinar-to-present-respect-glioblastoma-clinical-trial-update.jpg)
_plus-therapeutics-reports-first-quarter-2021-financial-results-and-business-highlights.jpg)
_saucer-x-travis-walton-trading-cards.jpg)
_plus-therapeutics-announces-initiation-of-final-cohort-of-respect-glioblastoma-trial.jpg)
_plus-therapeutics-enters-into-master-services-agreement-with-piramal-pharma-solutions-a-leading-cdmo.jpg)
_plus-therapeutics-respect-clinical-trial-data-to-be-presented-at-2020-sno-annual-meeting.jpg)
_from-blueprint-to-framework-learning-with-matthew-2239-2023-06-21-232351.jpg)
![[+]](/images/menu.gif){kind=small}